Bicara Therapeutics Inc. Common Stock (BCAX)
Automate Your Wheel Strategy on BCAX
With Tiblio's Option Bot, you can configure your own wheel strategy including BCAX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCAX
- Rev/Share 0.0
- Book/Share 8.428
- PB 1.3087
- Debt/Equity 0.0013
- CurrentRatio 24.621
- ROIC -0.2323
- MktCap 601534474.0
- FreeCF/Share -1.6374
- PFCF -6.746
- PE -6.6693
- Debt/Assets 0.0012
- DivYield 0
- ROE -0.2802
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | BCAX | Wells Fargo | Underweight | Equal Weight | -- | $8 | May 23, 2025 |
| Initiation | BCAX | Wells Fargo | -- | Underweight | -- | $8 | April 17, 2025 |
| Initiation | BCAX | Wedbush | -- | Outperform | -- | $31 | Feb. 6, 2025 |
| Initiation | BCAX | H.C. Wainwright | -- | Buy | -- | $42 | Dec. 6, 2024 |
| Initiation | BCAX | TD Cowen | -- | Buy | -- | -- | Oct. 8, 2024 |
| Initiation | BCAX | Morgan Stanley | -- | Overweight | -- | $35 | Oct. 8, 2024 |
| Initiation | BCAX | Stifel | -- | Buy | -- | $47 | Oct. 8, 2024 |
| Initiation | BCAX | Cantor Fitzgerald | -- | Overweight | -- | -- | Oct. 8, 2024 |
News
Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025
Published: June 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Median DOR of 21.7 months with 80% of responders achieving a deep response (≥80% tumor shrinkage) Depth and durability translating to prolonged OS with median OS of 21.3 months and 2-year OS of 46% in HPV-negative HNSCC Conference call and webcast today at 3:00 p.m. CT / 4:00 p.m.
Read More
Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset Company to host conference call on Sunday, June 1, 2025 at 3:00 p.m. CT / 4:00 p.m. ET to discuss fulsome dataset
Read More
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: April 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company's ongoing Phase 1/1b clinical trial of ficerafusp alfa in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30-June 3, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an …
Read More
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET.
Read More
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).
Read More
About Bicara Therapeutics Inc. Common Stock (BCAX)
- IPO Date
- Website https://www.bicara.com
- Industry Biotechnology
- CEO Ms. Claire Mazumdar Clemon M.B.A., Ph.D.
- Employees 55